Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Dermata Therapeutics, Inc. (DRMA : NSDQ)

• Company Description    Dermata Therapeutics, Inc. is a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions. Number of Employees: 8

• Price / Volume Information    Yesterday's Closing Price: $3.42 Daily Weekly Monthly 20 Day Moving Average: 336,412 shares Shares Outstanding: 0.68 (millions) Market Capitalization: $2.33 (millions) Beta: 0.54 52 Week High: $16.50 52 Week Low: $3.40 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -29.63% -30.91% 12 Week -47.03% -50.52% Year To Date -74.67% -78.22%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 3525 DEL MAR HEIGHTS ROAD SUITE 322 - SAN DIEGO,CA 92130 USA ph: 858-800-2543 fax: - sproehl@dermatarx.com http://www.dermatarx.com

• General Corporate Information    Officers Gerald T. Proehl - President; Chief Executive Officer and Chairman Kyri K. Van Hoose - Chief Financial Officer Wendell Wierenga - Director Mary Fisher - Director Steven J. Mento - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 249845504 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/12/25 Share - Related Items Shares Outstanding: 0.68 Most Recent Split Date: 8.00 (0.10:1) Beta: 0.54 Market Capitalization: $2.33 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/12/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.39 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 96.03% vs. Previous Quarter: 63.11% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - - 06/30/25 - -214.98 03/31/25 - -270.81 ROA 09/30/25 - - 06/30/25 - -153.76 03/31/25 - -179.96 Current Ratio 09/30/25 - - 06/30/25 - 6.47 03/31/25 - 3.70 Quick Ratio 09/30/25 - - 06/30/25 - 6.47 03/31/25 - 3.70 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - - 06/30/25 - 8.80 03/31/25 - 12.10 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©